AAAAAA

   
Results: 1-17 |
Results: 17
Carboxyamido-triazole (CAI)- a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells
Authors: Waselenko, JK Shinn, CA Willis, CR Flinn, IW Grever, MR Byrd, JC
Citation: Jk. Waselenko et al., Carboxyamido-triazole (CAI)- a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells, LEUK LYMPH, 42(5), 2001, pp. 1049-1053
Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
Authors: Byrd, JC Murphy, T Howard, RS Lucas, MS Goodrich, A Park, K Pearson, M Waselenko, JK Ling, G Grever, MR Grillo-Lopez, AJ Rosenberg, J Kunkel, L Flinn, IW
Citation: Jc. Byrd et al., Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity, J CL ONCOL, 19(8), 2001, pp. 2153-2164
Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia
Authors: Waselenko, JK Grever, MR Shinn, CA Flinn, IW Byrd, JC
Citation: Jk. Waselenko et al., Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia, LEUK RES, 25(6), 2001, pp. 435-440
Cytotoxic alkaloids from Tylophora indica
Authors: Ali, M Ansari, SH Grever, MR
Citation: M. Ali et al., Cytotoxic alkaloids from Tylophora indica, PHARMAZIE, 56(2), 2001, pp. 188-190
Novel therapeutic approaches for hematologic malignancies in the 21st century: Introduction
Authors: Byrd, JC Caligiuri, MA Grever, MR
Citation: Jc. Byrd et al., Novel therapeutic approaches for hematologic malignancies in the 21st century: Introduction, SEMIN ONCOL, 27(5), 2000, pp. 493-494
Novel therapies for chronic lymphocytic leukemia in the 21st century
Authors: Byrd, JC Waselenko, JK Keating, M Rai, K Grever, MR
Citation: Jc. Byrd et al., Novel therapies for chronic lymphocytic leukemia in the 21st century, SEMIN ONCOL, 27(5), 2000, pp. 587-597
Future development of pentostatin (Nipent): Opportunities for using a highly effective, safe agent for hematologic and autoimmune diseases - Introduction
Authors: Byrd, JC Grever, MR
Citation: Jc. Byrd et Mr. Grever, Future development of pentostatin (Nipent): Opportunities for using a highly effective, safe agent for hematologic and autoimmune diseases - Introduction, SEMIN ONCOL, 27(2), 2000, pp. 1-2
Pentostatin (Nipent): A review of potential toxicity and its management
Authors: Margolis, J Grever, MR
Citation: J. Margolis et Mr. Grever, Pentostatin (Nipent): A review of potential toxicity and its management, SEMIN ONCOL, 27(2), 2000, pp. 9-14
Theophylline, pentostatin (Nipent), and chlorambucil: A dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders
Authors: Byrd, JC Grever, MR Waselenko, JK Willis, CR Park, K Goodrich, A Lucas, MA Shinn, C Flinn, IW
Citation: Jc. Byrd et al., Theophylline, pentostatin (Nipent), and chlorambucil: A dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders, SEMIN ONCOL, 27(2), 2000, pp. 37-40
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia
Authors: Waselenko, JK Grever, MR Beer, M Lucas, MA Byrd, JC
Citation: Jk. Waselenko et al., Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia, SEMIN ONCOL, 27(2), 2000, pp. 44-51
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Authors: Alizadeh, AA Eisen, MB Davis, RE Ma, C Lossos, IS Rosenwald, A Boldrick, JG Sabet, H Tran, T Yu, X Powell, JI Yang, LM Marti, GE Moore, T Hudson, J Lu, LS Lewis, DB Tibshirani, R Sherlock, G Chan, WC Greiner, TC Weisenburger, DD Armitage, JO Warnke, R Levy, R Wilson, W Grever, MR Byrd, JC Botstein, D Brown, PO Staudt, LM
Citation: Aa. Alizadeh et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, NATURE, 403(6769), 2000, pp. 503-511
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin
Authors: Flinn, IW Kopecky, KJ Foucar, MK Head, D Bennett, JM Huchison, R Corbett, W Cassileth, P Habermann, T Golomb, H Rai, K Eisenhauer, E Appelbaum, F Cheson, B Grever, MR
Citation: Iw. Flinn et al., Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin, BLOOD, 96(9), 2000, pp. 2981-2986
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
Authors: Flinn, IW Byrd, JC Morrison, C Jamison, J Diehl, LF Murphy, T Piantadosi, S Seifter, E Ambinder, RF Vogelsang, G Grever, MR
Citation: Iw. Flinn et al., Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies, BLOOD, 96(1), 2000, pp. 71-75
Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease
Authors: Nousari, HC Brodsky, RA Jones, RJ Grever, MR Anhalt, GJ
Citation: Hc. Nousari et al., Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease, J AM ACAD D, 40(5), 1999, pp. 750-754
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
Authors: Karanes, C Kopecky, KJ Head, DR Grever, MR Hynes, HE Kraut, EH Vial, RH Lichtin, A Nand, S Samlowski, WE Appelbaum, FR
Citation: C. Karanes et al., A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia, LEUK RES, 23(9), 1999, pp. 787-794
Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
Authors: Byrd, JC Shinn, C Ravi, R Willis, CR Waselenko, JK Flinn, IW Dawson, NA Grever, MR
Citation: Jc. Byrd et al., Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells, BLOOD, 94(4), 1999, pp. 1401-1408
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study
Authors: Leith, CP Kopecky, KJ Chen, IM Eijdems, L Slovak, ML McConnell, TS Head, DR Weick, J Grever, MR Appelbaum, FR Willman, CL
Citation: Cp. Leith et al., Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study, BLOOD, 94(3), 1999, pp. 1086-1099
Risultati: 1-17 |